RecruitingPhase 3NCT06499285
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Studying Myelodysplastic neoplasm with increased blasts
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Takeda
- Principal Investigator
- Study DirectorTakeda
- Intervention
- Elritercept(drug)
- Enrollment
- 225 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2032
Study locations (30)
- City of Hope, Duarte, California, United States
- Los Angeles Cancer Network, Glendale, California, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States
- University of Miami Hospital and Clinics, Miami, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- ILCC. Illinois Cancer Centers, Peoria, Illinois, United States
- Norton Cancer Institute, Louisville, Kentucky, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- Maryland Oncology Hematolofy, Columbia, Maryland, United States
- Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States
- Clinical Research Alliance NY, Westbury, New York, United States
- Gabrail Cancer Center Research, Canton, Ohio, United States
- Cleveland Clinic - Cleveland, Cleveland, Ohio, United States
- Tennessee Cancer Specialists, Knoxville, Tennessee, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06499285 on ClinicalTrials.govOther trials for Myelodysplastic neoplasm with increased blasts
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07511829WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory Study to Improve Quality of Life and the Efficacy of Transfusion Supportive Care in People With Blood Cancers Undergoing TreatmentUniversity of Oxford
- RECRUITINGPHASE2NCT06717958Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) MutationTechnische Universität Dresden
- RECRUITINGPHASE1NCT06616636A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)M.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT06138587Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationDana-Farber Cancer Institute
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05782127Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic SyndromesGroupe Francophone des Myelodysplasies
- ACTIVE NOT RECRUITINGPHASE3NCT05949684ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood TransfusionsBristol-Myers Squibb
- ACTIVE NOT RECRUITINGPHASE2NCT04994808Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid LeukemiaFred Hutchinson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT05379166Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic SyndromeUma Borate
See all trials for Myelodysplastic neoplasm with increased blasts →